Acomplia (Rimonabant) was approved for sale in the UK on June which means the introduction of this drug is new. Acomplia has not yet got FDA (Food and Drug Administration) approval for sale in the US. Sanofi-Aventis is the manufacturer of Acomplia, which is a French pharmaceutical firm. The drug is prescribed for suppressing appetite in an obese person. The suppression of appetite helps in lowering calorie intake thereby reducing obesity. During its trial period the manufacturer also claimed of this drug having smoking cessation effect.As the introduction of this drug is new the success of this drug remains to be seen. acomplia drug loss weight ,but the real problem is the availability of the drug. At present only a few numbers of pharmacies are keeping it with them as FDA has not approved its use as a weight loss pill. Till the moment when FDA approves the drug, the pharmacies in US would be having tough time assuring the customers of its arrival soon.

The clinical results of Acomplia (Rimonabant) for 2 years showed much promise for this new weight loss drug. In the clinical trials around 40% of the sample lost 10% or more weight as a result of taking the drug. Apart from that the cardiovascular and metabolic risk factors related to obesity are minimised. These all are leading to a wide spread notion that Acomplia would help an obese person get slimmer when taken. The initial results of the effects of Acomplia from EU and UK is satisfactory to Sanofi-Aventis standards. But the success stories which are remaining to be unfolded from UK and EU where it has been launched last month, would only state whether this diet pill Acomplia would stand the test of time.

Howsoever successful the effects of acomplia drug loss weight may be as a weight loss pill there certainly would be some side effects like nausea, dizziness, insomnia and stomach upset etc. which a user might have to deal with. But the side effects have much lower intensity than other similar diet pills. The pill must be taken with consultation of a doctor to get its maximum effect on weight loss. A person with heart disease, blood pressure, diabetes, allergy and hypertension should tell a doctor first before going for the drug. Children, pregnant woman and breast feeding mothers too should consult doctor if they are to take the pill.

Acomplia (Rimonabant) is the latest weight loss drug developed by French pharmaceutical major Sanofi-Aventis. It has been introduced in UK and EU market and is pending FDA approval for sale in US. As the drug is new the result of its effect remains to be seen.

August 12, 2007 — Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the latest developments in the commercially marketed cannabinoids, in particular, Acomplia® (Rimonabant).”Rimonabant: The first of the Cannabinoid blockbusters” forecasts that in 2007, the cannabinoid market will generate $709 million revenue in sales. This represents a 45% growth from 2006, when this class of drugs brought in $386 million.

Authors of the report say that cannabinoids like Acomplia®, Marinol®, Cesamet®, and Sativex® treat a variety of medical conditions ranging from weight-loss to pain relief. They note that there is a significant change in the attitude towards these drugs, and this increased acceptance will help achieve greater market penetration. The study predicts that increased usage will see Rimonabant, achieve blockbuster drug status before the end of the decade, making it the first cannabinoid to do so.

Analysts say Sanofi-Aventis’ acomplia(R) drug loss weight, which is used to treat obesity, is set to raise the profile of the market with impressive sales. Branded Zimulti in the U.S, acomplia drug loss weight ,Rimonabant has now been approved for sale in all 25 countries of the European Union by the European Commission.

The report states that the growth this class of products has not yet achieved its full potential, and highlights the treatment areas that are likely to benefit from R&D efforts around the medicinal cannabinoids. It also documents products currently coming through the pipeline with predictions of their market potential,acomplia drug loss weight.

The study features an in-depth review of the cannabinoids market touching on the market potential for this class of drugs to treat various diseases. It brings to light the results of the latest clinical trials and experimental research surrounding these drugs and estimates the future worth of the global cannabinoid market with revenue forecasts to 2012. The regulatory issues governing the use of medicinal cannabis in eight major markets are also covered by this report.